Therapeutic application of genome editing in dyslipidemia.
| Autor: | Whittaker MN; Department of Bioengineering, School of Engineering and Applied Science., Musunuru K; Cardiovascular Institute, Department of Medicine, and Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current opinion in lipidology [Curr Opin Lipidol] 2022 Apr 01; Vol. 33 (2), pp. 133-138. |
| DOI: | 10.1097/MOL.0000000000000805 |
| Abstrakt: | Purpose of Review: To summarize recent advances with respect to the use of genome editing to modify blood lipid levels in vivo. Recent Findings: Genome-editing technologies have been successfully used to target the PCSK9 gene in the livers of nonhuman primates and significantly reduce blood LDL cholesterol levels. Summary: Multiple proof-of-concept nonhuman primate studies raise the prospect of genome editing empowering 'one-and-done' therapies for the treatment of dyslipidemic patients. (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|